Stock listing
NASDAQ:GRI GRI Bio, Inc. Stock
Home listing (NASDAQ) of GRI Bio, Inc.
Follow GRI Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:GRI
$1.12 USD -0.15 (-11.8%)
Close on Nov 20, 2026
- Day range
- $1.12 – $1.25 USDNov 20, 2026
- Volume
- 25,075 sharesNov 20, 2026
- Market cap
- $2.45M USDAt the close on Nov 20, 2026 · price × 2.19M shares outstanding
- 52-week range
- $1.12 – $64.12 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $526,803 USDMedian day 48,379 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:GRI · Home | $1.12 USD | -0.15 (-11.8%) | 25,075 | $1.25 | $1.25 | $1.12 | $1.27 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:GRI · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.12 | -0.15 | -11.8% | $1.25 | $1.25 | $1.12 | 25,075 | |
| $1.27 | -0.08 | -5.9% | $1.303 | $1.329 | $1.25 | 26,577 | |
| $1.35 | -0.05 | -3.5% | $1.445 | $1.45 | $1.33 | 24,265 | |
| $1.40 | -0.30 | -17.6% | $1.63 | $1.63 | $1.38 | 115,586 | |
| $1.70 | -0.12 | -6.6% | $1.79 | $1.83 | $1.70 | 21,792 | |
| $1.82 | -0.01 | -0.5% | $1.73 | $1.88 | $1.72 | 48,019 | |
| $1.83 | -0.06 | -3.2% | $1.896 | $1.971 | $1.72 | 56,057 | |
| $1.89 | +0.18 | +10.5% | $1.85 | $1.91 | $1.75 | 57,248 | |
| $1.71 | -0.17 | -9.0% | $1.84 | $1.872 | $1.71 | 37,457 | |
| $1.88 | +0.33 | +21.3% | $1.56 | $1.94 | $1.56 | 43,234 | |
| $1.55 | +0.12 | +8.4% | $1.47 | $1.67 | $1.47 | 128,793 | |
| $1.43 | -0.11 | -7.1% | $1.53 | $1.54 | $1.36 | 48,379 | |
| $1.54 | +0.08 | +5.5% | $1.47 | $1.552 | $1.42 | 52,114 | |
| $1.46 | -0.07 | -4.6% | $1.529 | $1.56 | $1.46 | 12,122 | |
| $1.53 | -0.04 | -2.5% | $1.59 | $1.59 | $1.45 | 28,212 | |
| $1.57 | -0.055 | -3.4% | $1.60 | $1.65 | $1.57 | 21,991 | |
| $1.625 | +0.045 | +2.8% | $1.57 | $1.66 | $1.57 | 6,260 | |
| $1.58 | +0.08 | +5.3% | $1.51 | $1.629 | $1.487 | 33,197 | |
| $1.50 | +0.05 | +3.4% | $1.47 | $1.52 | $1.44 | 11,644 | |
| $1.45 | +0.03 | +2.1% | $1.45 | $1.53 | $1.422 | 64,900 | |
| $1.42 | -0.05 | -3.4% | $1.46 | $1.47 | $1.385 | 102,300 | |
| $1.47 | +0.01 | +0.7% | $1.58 | $1.58 | $1.46 | 59,000 | |
| $1.46 | +0.01 | +0.7% | $1.45 | $1.538 | $1.45 | 46,700 | |
| $1.45 | +0.07 | +5.1% | $1.37 | $1.50 | $1.36 | 42,600 | |
| $1.38 | -0.02 | -1.4% | $1.485 | $1.56 | $1.37 | 44,300 | |
| $1.40 | 0.00 | 0.0% | $1.43 | $1.45 | $1.38 | 28,500 | |
| $1.40 | -0.15 | -9.7% | $1.54 | $1.56 | $1.40 | 50,500 | |
| $1.55 | -0.02 | -1.3% | $1.60 | $1.60 | $1.52 | 28,900 | |
| $1.57 | -0.17 | -9.8% | $1.75 | $1.75 | $1.55 | 64,500 | |
| $1.74 | +0.06 | +3.6% | $1.71 | $1.76 | $1.70 | 21,300 | |
| $1.68 | -0.17 | -9.2% | $1.85 | $1.88 | $1.68 | 54,500 | |
| $1.85 | -0.05 | -2.6% | $1.88 | $1.92 | $1.85 | 31,500 | |
| $1.90 | -0.01 | -0.5% | $1.91 | $1.975 | $1.88 | 18,200 | |
| $1.91 | -0.05 | -2.6% | $2.04 | $2.04 | $1.88 | 84,600 | |
| $1.96 | 0.00 | 0.0% | $2.00 | $2.02 | $1.95 | 38,400 | |
| $1.96 | +0.03 | +1.6% | $1.93 | $1.97 | $1.91 | 20,300 | |
| $1.93 | -0.07 | -3.5% | $2.05 | $2.05 | $1.92 | 35,400 | |
| $2.00 | -0.10 | -4.8% | $2.09 | $2.106 | $2.00 | 25,600 | |
| $2.10 | +0.05 | +2.4% | $2.07 | $2.25 | $2.00 | 118,100 | |
| $2.05 | -0.04 | -1.9% | $2.07 | $2.08 | $1.95 | 53,300 | |
| $2.09 | -0.06 | -2.8% | $2.13 | $2.18 | $2.025 | 31,000 | |
| $2.15 | +0.10 | +4.9% | $2.05 | $2.19 | $1.95 | 143,400 | |
| $2.05 | +0.11 | +5.7% | $1.96 | $2.06 | $1.93 | 106,500 | |
| $1.94 | +0.01 | +0.5% | $2.00 | $2.19 | $1.85 | 260,800 | |
| $1.93 | +0.09 | +4.9% | $1.86 | $1.96 | $1.77 | 113,400 | |
| $1.84 | +0.03 | +1.7% | $1.77 | $1.91 | $1.72 | 174,200 | |
| $1.81 | -0.01 | -0.5% | $1.81 | $1.85 | $1.75 | 47,100 | |
| $1.82 | -0.07 | -3.7% | $1.89 | $1.89 | $1.80 | 69,300 | |
| $1.89 | -0.01 | -0.5% | $1.86 | $1.97 | $1.86 | 103,500 | |
| $1.90 | -0.04 | -2.1% | $1.99 | $2.05 | $1.85 | 131,700 | |
| $1.94 | +0.14 | +7.8% | $1.79 | $2.00 | $1.78 | 213,600 | |
| $1.80 | -0.20 | -10.0% | $1.97 | $1.97 | $1.76 | 199,500 | |
| $2.00 | -0.88 | -30.6% | $2.61 | $2.67 | $1.90 | 727,800 | |
| $2.88 | +0.59 | +25.8% | $2.34 | $3.36 | $2.33 | 7,464,800 | |
| $2.29 | +0.29 | +14.5% | $2.08 | $2.50 | $2.01 | 1,599,900 | |
| $2.00 | +0.09 | +4.7% | $1.92 | $2.02 | $1.87 | 85,800 | |
| $1.91 | -0.01 | -0.5% | $1.90 | $1.98 | $1.84 | 40,300 | |
| $1.92 | 0.00 | 0.0% | $1.93 | $1.97 | $1.86 | 43,000 | |
| $1.92 | -0.15 | -7.2% | $2.05 | $2.07 | $1.91 | 33,500 | |
| $2.07 | +0.16 | +8.4% | $1.821 | $2.10 | $1.821 | 78,500 | |
| $1.91 | -0.05 | -2.6% | $1.96 | $1.96 | $1.83 | 44,200 | |
| $1.96 | +0.17 | +9.5% | $1.80 | $1.98 | $1.785 | 126,500 | |
| $1.79 | +0.14 | +8.5% | $1.80 | $1.94 | $1.759 | 264,300 | |
| $1.65 | -0.02 | -1.2% | $1.71 | $1.73 | $1.65 | 83,100 | |
| $1.67 | -0.06 | -3.5% | $1.73 | $1.77 | $1.664 | 27,500 |
Splits
5 splits since 2023 · NASDAQ:GRI · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-28 | Consolidation | |
| 1-for-17 | Consolidation | |
| 1-for-13 | Consolidation | |
| 1-for-7 | Consolidation | |
| 1-for-30 | Consolidation |
- Ticker
- NASDAQ:GRI
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Sep 28, 2026
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Latest deck · Sep 8, 2026
Investor Presentation (September 2026)
Investor deck · 21 slides
Latest news
GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit
Sep 28, 2026
Closed $2.10 (+2.4%) on Sep 28, 2026
GRI Bio Featured in "Why Now" On-Demand Video Webcast
Aug 27, 2026
Closed $2.07 (+8.4%) on Aug 27, 2026
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
Aug 24, 2026
Closed $1.79 (+8.5%) on Aug 24, 2026
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Jun 18, 2026
Closed $1.88 (-19.0%) on Jun 18, 2026
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026
Closed $2.14 (+5.4%) on May 18, 2026
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Apr 8, 2026
Closed $2.40 (+4.3%) on Apr 8, 2026
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
Feb 17, 2026
Closed $2.31 (0.0%) on Feb 17, 2026
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
Feb 5, 2026
Closed $2.19 (-17.0%) on Feb 5, 2026
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Feb 4, 2026
Closed $2.64 (+1.5%) on Feb 4, 2026
GRI Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 48 in all · newest Sep 28, 2026 · oldest 2021
- Decks
- 8 decks · latest Sep 8, 2026
Where GRI Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:GRI · Home listing · This page | NASDAQ | United States | USD |
| BOATS:GRI | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 0.5×: 2nd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$6.99M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.89
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| GRI Bio, Inc. · NASDAQ:GRI | US$2.45M | −US$6.99M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.89 |
| BioAtla, Inc. · NASDAQ:BCAB | US$2.58M | US$2.01M | n/a | n/a | n/a | n/a | n/a | n/a | -0.34 |
| Invion Ltd. · ASX:IVX | US$2.49M | US$3.12M | n/a | 12.2× | n/a | 0.7× | n/a | 0.3× | n/a |
| NeuroSense Therapeutics Ltd. · NASDAQ:NRSN | US$2.43M | US$2.20M | n/a | n/a | n/a | n/a | n/a | n/a | 1.41 |
| ValiRx PLC · LSE:VAL | US$2.42M | US$1.15M | n/a | 28.0× | n/a | 0.6× | n/a | 0.0× | n/a |
| BSF Enterprise PLC · LSE:BSFA | US$2.40M | US$2.95M | n/a | 42.7× | n/a | 1.0× | n/a | 0.3× | n/a |
| Revelation Biosciences, Inc. · NASDAQ:REVB | US$2.39M | −US$5.92M | n/a | n/a | n/a | 0.3× | n/a | 0.1× | 1.66 |
| Mustang Bio, Inc. · NASDAQ:MBIO | US$2.38M | −US$11.89M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 1.01 |
| Quest PharmaTech Inc. · TSXV:QPT | US$2.36M | US$2.30M | 0.7× | n/a | n/a | 0.1× | n/a | 0.0× | 1.90 |
| HCW Biologics Inc. · NASDAQ:HCWB | US$2.35M | US$8.23M | n/a | 1.2× | n/a | 0.3× | −63.4% | 1.0× | 1.19 |
| Ernexa Therapeutics Inc. · NASDAQ:ERNA | US$2.30M | −US$2.96M | n/a | n/a | n/a | 0.5× | n/a | 0.1× | 0.86 |
| Median of the others | US$2.40M | US$2.10M | 0.7× | 20.1× | 0.5× | −63.4% | 0.1× | 1.19 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.
- Price target
- 18.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.90 · 2 analysts
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 · After close | −17.6% |
| Q2 2026 | Aug 14, 2026 · Before open | −5.7% |
| Q1 2026 | May 13, 2026 · After close | −4.9% |
| Q4 2025 | Jan 30, 2026 · Before open | −1.8% |
| Q3 2025 | Nov 14, 2025 · Before open | 0.0% |
| Q2 2025 | Aug 14, 2025 · Before open | +10.8% |
| Q1 2025 | May 15, 2025 · Before open | −1.4% |
| Q4 2024 | Mar 26, 2025 · After close | −1.3% |
| Q3 2024 | Nov 14, 2024 · After close | −19.6% |
| Q2 2024 | Aug 14, 2024 · Before open | −7.6% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | −0.5% |
| Q4 2023 | Feb 22, 2024 · Before open | −12.0% |
| Q3 2023 | Nov 14, 2023 · After close | −6.5% |
| Q2 2023 | Aug 8, 2023 | −19.7% |
| Q1 2023 | May 10, 2023 | −3.3% |
| Q4 2022 | Feb 23, 2023 | 0.0% |
| Q3 2022 | Nov 3, 2022 | −3.1% |
| Q2 2022 | Jul 28, 2022 | −7.6% |
| Q1 2022 | May 9, 2022 | 0.0% |
| Q4 2021 | Feb 14, 2022 | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2026) | Investor deck | 21 slides | Sep 8, 2026 |
| Investor Presentation (August 2025) | Investor deck | 23 slides | Aug 20, 2025 |
| Investor Presentation (August 2024) | Investor deck | 25 slides | Aug 14, 2024 |
| Investor Presentation (May 2024) | Investor deck | 25 slides | May 13, 2024 |
| Investor Presentation (January 2024) | Investor deck | 28 slides | Jan 16, 2024 |
| Investor Presentation (August 2023) | Investor deck | 28 slides | Aug 25, 2023 |
| Investor Presentation (April 2023) | Investor deck | 22 slides | Apr 27, 2023 |
| Vallon Pharmaceuticals — Merger or Acquisition (December 2022) | Merger or acquisition | 24 slides | Dec 13, 2022 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock (or common stock equivalents) and Series F warrants Closed: US$8M raised · US$0.75 a share · Warrants at US$0.75 for 60 months · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product candidate development, working capital and general corporate purposes | Dec 12, 2025 |
| Public offering of shares of common stock (or common stock equivalents) and accompanying Series E-1, E-2 and E-3 warrants Closed: US$5M raised · US$3.6 a share · Warrants at US$3.2 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: Product candidate development, working capital and general corporate purposes | Apr 2, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Vallon Pharmaceuticals, Inc. Priced at US$8.00 a share on Feb 9, 2021.
- Price
- US$8.00 a share
- Shares offered
- 2,250,000 shares of common stock
- Offering size
- US$18 million
- Underwriters' option
- Up to 337,500 more shares
- Listing
- VLON on the Nasdaq Capital Market
- Underwriter
- ThinkEquity
- Shares delivered
- On or about Feb 12, 2021
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 11, 2020 |
| Filed publicly | Oct 23, 2020 |
| Amended 3 times | Newest Jan 28, 2021 |
| Shares registered with an exchange | Feb 8, 2021 |
| Declared effective by the SEC | Feb 9, 2021 |
| Final prospectus, with the price | Feb 11, 2021 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 11, 2021 |
| EFFECT · Notice that a registration is effective | Feb 9, 2021 |
| S-1MEF · Registration of more shares for the same offering | Feb 9, 2021 |
| CERT · Exchange's certificate of listing | Feb 9, 2021 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 8, 2021 |
| CORRESP · Letter to the SEC | Feb 3, 2021 |
| CORRESP · Letter to the SEC | Feb 3, 2021 |
| CORRESP · Letter to the SEC | Feb 2, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
| CORRESP · Letter to the SEC | Feb 1, 2021 |
All 22 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jan 28, 2021 |
| S-1/A · Registration statement, amended | Jan 28, 2021 |
| UPLOAD · Letter from the SEC | Jan 22, 2021 |
| FWP · Free writing prospectus | Jan 21, 2021 |
| S-1/A · Registration statement, amended | Jan 14, 2021 |
| CORRESP · Letter to the SEC | Nov 16, 2020 |
| S-1/A · Registration statement, amended | Nov 16, 2020 |
| UPLOAD · Letter from the SEC | Nov 6, 2020 |
| CORRESP · Letter to the SEC | Oct 23, 2020 |
| S-1 · Registration statement | Oct 23, 2020 |
| UPLOAD · Letter from the SEC | Oct 9, 2020 |
| DRS · Draft registration statement | Sep 11, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 11, 2021
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 22.5M | 21.8M | 0 | 0 | 100.0K | ||
| Cost of revenue | 4.00K | 4.00K | 57.0K | 50.0K | 73.0K | 100.0K | 735 | 612 |
| Gross profit | -4.00K | -4.00K | -57.0K | -50.0K | -73.0K | 100.0K | -735 | -612 |
| Research and development | 6.82M | 3.77M | 3.23M | 242.0K | 5.19M | 3.71M | 1.88M | 3.51M |
| Selling, general and administrative | 5.16M | 4.47M | 8.15M | 2.00M | 813.0K | 1.20M | ||
| Operating income | -12.0M | -8.23M | -11.4M | -2.24M | -9.26M | -4.79M | -3.15M | -4.31M |
| Depreciation and amortization | 4.00K | 4.00K | 4.00K | 3.00K | 73.0K | 75.0K | 735 | 612 |
| EBITDA | -12.0M | -8.23M | -11.4M | -2.24M | -9.19M | -4.71M | -3.15M | -4.31M |
| Interest expense | 6.00K | 2.08M | 653.0K | 547.0K | 34.0K | 197.0K | ||
| Income before tax | -12.0M | -8.21M | -13.0M | -3.22M | -1.56M | -2.53M | -3.46M | -4.31M |
| Income tax | 3.00K | 2.00K | 2.77M | 325.0K | -50.0K | -131.3K | 5 | -2 |
| Net income | -12.0M | -8.21M | -13.0M | -3.22M | -9.30M | -4.82M | -3.46M | -4.31M |
| Earnings per share, basic | -121.80 | -1,545.55 | -5,018.09 | -24.95 | -1.42 | -1.07 | ||
| Earnings per share, diluted | -121.80 | -1,545.55 | -5,018.09 | -24.95 | -1.42 | -1.07 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.23M | 5.03M | 1.81M | 9.00K | 3.70M | 109.0K | 3.82M | 612.7K |
| Short-term investments | 0 | 3.81M | 0 | |||||
| Current assets | 8.59M | 5.62M | 2.93M | 312.0K | 8.13M | 674.0K | 3.92M | 637.6K |
| Property, plant and equipment | 3.00K | 4.00K | 8.00K | 4.00K | 0 | 2.00K | ||
| Total assets | 8.67M | 5.74M | 2.96M | 383.0K | 8.34M | 955.0K | 4.28M | 639.2K |
| Accounts payable | 1.84M | 897.0K | 1.41M | 1.29M | 918.0K | 1.23M | 246.3K | 286.6K |
| Current liabilities | 2.64M | 1.64M | 2.70M | 1.99M | 2.44M | 2.23M | 807.5K | 486.3K |
| Total debt | 71.0K | 119.0K | 14.0K | 673.0K | 3.61M | 336.0K | 340.0K | |
| Total liabilities | 2.66M | 1.71M | 2.70M | 2.01M | 2.52M | 2.41M | 1.06M | 486.3K |
| Shareholders' equity | 6.01M | 4.03M | 259.0K | -1.63M | -4.85M | -1.45M | 3.21M | 152.9K |
| Shares outstanding | 497.7K | 18.8K | 2.91K | 142.8K | 6.81M | 4.51M | 891 | 891 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.2M | -8.61M | -8.99M | -1.08M | -8.31M | -3.71M | -2.88M | -2.37M |
| Capital spending | -3.00K | 0 | -8.00K | -3.00K | 0 | -2.00K | -5 | -2.21K |
| Free cash flow | -10.2M | -8.61M | -9.00M | -1.09M | -8.31M | -3.71M | -2.88M | -2.37M |
| Cash from investing | -3.00K | 0 | -8.00K | -3.00K | -3.84M | -2.00K | -2.20K | |
| Cash from financing | 13.4M | 11.8M | 10.8M | 1.01M | 15.7M | -4.00K | 6.09M | 2.99M |
| Dividends paid | -2.92M | -3.45M | ||||||
| Share buybacks | -1.00K | -1.00K | 0 | -124.0K | 0 | |||
| Change in cash | 3.20M | 3.22M | 1.80M | -81.0K | 3.59M | -3.71M | 3.21M | 612.7K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2026 | Management or board change | SEC |
| ARS · Annual report to shareholders | Sep 28, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 28, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 18, 2026 | Current report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Feb 2, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 30, 2026 | Other filings | SEC |
| 10-K · Annual report | Jan 30, 2026 | Annual report | SEC |
| 8-K · Current report | Jan 29, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 29, 2026 | Offer document | SEC |
| S-3 · Registration statement | Jan 29, 2026 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jan 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 28, 2026 | Current report | SEC |
| 8-K · Current report | Jan 21, 2026 | Current report | SEC |
| 8-K · Current report | Jan 16, 2026 | Current report | SEC |
| 8-K · Current report | Jan 15, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jan 9, 2026 | Current report | SEC |
| 424B5 · Prospectus | Jan 9, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 29, 2025 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Dec 29, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Dec 19, 2025 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 17, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| 424B4 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 12, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Dec 9, 2025 | Offer document | SEC |
| S-1 · Registration statement | Dec 8, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Dec 8, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 8-K · Current report | Dec 2, 2025 | Current report | SEC |
| 424B3 · Prospectus | Nov 14, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 14, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 27, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 22, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| DRSLTR · Letter to the SEC with a draft | Aug 15, 2025 | Other filings | SEC |
| DRS · Draft registration statement | Aug 15, 2025 | Offer document | SEC |
| 424B3 · Prospectus | Aug 15, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Aug 13, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 13, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 31, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Jul 11, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Jul 11, 2025 | Meeting notice | SEC |
| 8-K · Current report | Jun 26, 2025 | Current report | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 23, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| 8-K · Current report | May 5, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 5, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 15, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 7, 2025 | Big-stake notice | SEC |
| 424B4 · Prospectus | Apr 2, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Apr 2, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 26, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 26, 2025 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 26, 2025 | Offer document | SEC |
| S-1 · Registration statement | Mar 25, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 18, 2025 | Other filings | SEC |
| 8-K · Current report | Mar 17, 2025 | Results | SEC |
| DRS · Draft registration statement | Mar 14, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 14, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 11, 2025 | Current report | SEC |
| 8-K · Current report | Feb 19, 2025 | Current report | SEC |
| 8-K · Current report | Feb 11, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 24, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Jan 17, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Jan 7, 2025 | Meeting notice | SEC |
| S-8 · Registration statement for employee plans | Jan 6, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 20, 2024 | Current report | SEC |
| 424B5 · Prospectus | Dec 20, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 20, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 15, 2024 | Offer document | SEC |
| S-3 · Registration statement | Nov 14, 2024 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| D | Oct 25, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 24, 2024 | Current report | SEC |
| 8-K · Current report | Oct 22, 2024 | Material contract | SEC |
| 8-K/A · Current report, amended | Sep 11, 2024 | Current report | SEC |
| 424B3 · Prospectus | Sep 10, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Sep 10, 2024 | Offer document | SEC |
| 8-K · Current report | Sep 10, 2024 | Current report | SEC |
| 8-K · Current report | Sep 6, 2024 | Meeting outcome | SEC |
| 424B3 · Prospectus | Aug 28, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 28, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Aug 28, 2024 | Offer document | SEC |
| DEFA14A · Additional proxy material | Aug 23, 2024 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Aug 23, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 23, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Aug 16, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 13, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Aug 2, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 2, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 26, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jul 26, 2024 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Jul 23, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jul 19, 2024 | Current report | SEC |
| 424B5 · Prospectus | Jul 19, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| 424B4 · Prospectus | Jun 27, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 27, 2024 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Jun 27, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 26, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jun 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 25, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jun 25, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jun 24, 2024 | Other filings | SEC |
| S-1 · Registration statement | Jun 18, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jun 18, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jun 18, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 18, 2024 | Management or board change | SEC |
| 424B3 · Prospectus | Jun 14, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jun 14, 2024 | Offer document | SEC |
| 8-K · Current report | Jun 14, 2024 | Current report | SEC |
| 8-K · Current report | Jun 7, 2024 | Meeting outcome | SEC |
| 424B3 · Prospectus | May 31, 2024 | Offer document | SEC |
| 424B3 · Prospectus | May 31, 2024 | Offer document | SEC |
| 8-K · Current report | May 22, 2024 | Current report | SEC |
| 424B3 · Prospectus | May 20, 2024 | Offer document | SEC |
| 424B3 · Prospectus | May 20, 2024 | Offer document | SEC |
| 8-K · Current report | May 20, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 20, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 17, 2024 | Other filings | SEC |
| 424B3 · Prospectus | May 14, 2024 | Offer document | SEC |
| 424B3 · Prospectus | May 14, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | May 14, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 14, 2024 | Other filings | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| S-3 · Registration statement | May 10, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| DEF 14A · Proxy statement | May 9, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Results | SEC |
| 424B3 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 424B3 · Prospectus | Feb 2, 2024 | Offer document | SEC |
| 8-K · Current report | Feb 2, 2024 | Material contract | SEC |
| 424B4 · Prospectus | Feb 2, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 2, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 31, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 30, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 30, 2024 | Offer document | SEC |
| 424B3 · Prospectus | Jan 30, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jan 19, 2024 | Offer document | SEC |
| 8-K · Current report | Jan 19, 2024 | Meeting outcome | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
This page holds 200 of 409 filings. Open Filings
Cap table
Built by 6ix from GRI Bio, Inc.’s releases · as of Nov 12, 2026
- Common shares
- 2,186,115
- Fully diluted
- 2,186,115
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 2,186,115 | Nov 12, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.75 · expire about Dec 2030 |
| Warrants · US$3.20 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 12, 2026 | 2,186,115 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Marella Thorell Other companies: Carisma Therapeutics, Inc. (Director · Since at least Jun 30, 2024); Seres Therapeutics, Inc. (EVP, Chief Financial Officer · Since at least Mar 25, 2024); ESSA Pharma Inc (Director · Since at least Oct 1, 2020); Evelo Biosciences, Inc. (Chief Financial Officer · Jul 13, 2022 – Nov 7, 2023 · Past); Centessa Pharmaceuticals PLC (Chief Accounting Officer · May 27, 2021 – Mar 21, 2022 · Past) | Director · Feb 9, 2021 – Dec 13, 2022 · Past |
| David Szekeres Other companies: Connect Biopharma Holdings Limited (PRESIDENT · Since at least Mar 31, 2025); Heron Therapeutics, Inc. (EVP, Chief Operating Officer · Oct 13, 2020 – Jul 13, 2023 · Past); Regulus Therapeutics Inc (Chief Business Officer & GC · Mar 10, 2014 – Dec 2, 2014 · Past) | Director · Since at least Apr 21, 2023 |
| Camilla V. Simpson Other companies: Spruce Biosciences, Inc. (Director · Since at least Oct 8, 2020) | Director · Since at least Apr 21, 2023 |
| Joe Payne Other companies: Arcturus Therapeutics Holdings Inc. (President and CEO, Director · Since at least Jan 1, 2019) | Director · Feb 9, 2021 – Jun 9, 2022 · Past |
| Leanne Kelly | Chief Financial Officer · Since at least Aug 26, 2025 |
| Penny Toren | SVP, Regul Affairs & Prog Mgmt · Feb 9, 2021 – May 14, 2021 · Past |
| Roelof Rongen | Director · Since at least Apr 21, 2023 |
| Vipin Chaturvedi | Chief Scientific Officer · Since at least Apr 21, 2023 |
| Walter Marc Hertz | Chief Executive Officer, Director · Since at least Apr 21, 2023 |
Log in to ask 6ix AI your own questions about GRI Bio, Inc.